DE10204276A1 - N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel - Google Patents

N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel

Info

Publication number
DE10204276A1
DE10204276A1 DE10204276A DE10204276A DE10204276A1 DE 10204276 A1 DE10204276 A1 DE 10204276A1 DE 10204276 A DE10204276 A DE 10204276A DE 10204276 A DE10204276 A DE 10204276A DE 10204276 A1 DE10204276 A1 DE 10204276A1
Authority
DE
Germany
Prior art keywords
methyl
hydrogen
compounds
optionally
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10204276A
Other languages
German (de)
English (en)
Inventor
Adrian Carter
Helmut Ensinger
Matthias Grauert
Detlef Andre Stiller
Thomas Weiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10204276A priority Critical patent/DE10204276A1/de
Priority to PCT/EP2003/000538 priority patent/WO2003066599A1/de
Priority to CA002474687A priority patent/CA2474687A1/en
Priority to EP03737261A priority patent/EP1474398A1/de
Priority to AU2003215540A priority patent/AU2003215540A1/en
Priority to JP2003565973A priority patent/JP2005517013A/ja
Priority to US10/354,516 priority patent/US6683089B2/en
Priority to PE2003000102A priority patent/PE20030991A1/es
Priority to TW092102219A priority patent/TW200303203A/zh
Priority to ARP030100290A priority patent/AR038381A1/es
Priority to UY27637A priority patent/UY27637A1/es
Publication of DE10204276A1 publication Critical patent/DE10204276A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE10204276A 2002-02-02 2002-02-02 N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel Withdrawn DE10204276A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE10204276A DE10204276A1 (de) 2002-02-02 2002-02-02 N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
PCT/EP2003/000538 WO2003066599A1 (de) 2002-02-02 2003-01-21 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine und ihre verwendung als arzneimittel
CA002474687A CA2474687A1 (en) 2002-02-02 2003-01-21 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of thereof as medicaments
EP03737261A EP1474398A1 (de) 2002-02-02 2003-01-21 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine und ihre verwendung als arzneimittel
AU2003215540A AU2003215540A1 (en) 2002-02-02 2003-01-21 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of the same as pharmaceuticals
JP2003565973A JP2005517013A (ja) 2002-02-02 2003-01-21 Ｎ−アリルオキシエチル−１，２，３，４，５，６−ヘキサヒドロ−２，６−メタノ−３−ベンズアゾシン及びその薬剤としての使用
US10/354,516 US6683089B2 (en) 2002-02-02 2003-01-30 N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
PE2003000102A PE20030991A1 (es) 2002-02-02 2003-01-30 N-aliloxietil-1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocinas y su uso como medicamento
TW092102219A TW200303203A (en) 2002-02-02 2003-01-30 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine and use thereof as medicaments
ARP030100290A AR038381A1 (es) 2002-02-02 2003-01-31 N-aliloxietil-1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocinas y su uso como medicamento
UY27637A UY27637A1 (es) 2002-02-02 2003-01-31 N-aliloxietil-1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocinas y su uso como medicamento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10204276A DE10204276A1 (de) 2002-02-02 2002-02-02 N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
DE10204276A1 true DE10204276A1 (de) 2003-08-07

Family

ID=7713598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10204276A Withdrawn DE10204276A1 (de) 2002-02-02 2002-02-02 N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel

Country Status (10)

Country Link
EP (1) EP1474398A1 (ja)
JP (1) JP2005517013A (ja)
AR (1) AR038381A1 (ja)
AU (1) AU2003215540A1 (ja)
CA (1) CA2474687A1 (ja)
DE (1) DE10204276A1 (ja)
PE (1) PE20030991A1 (ja)
TW (1) TW200303203A (ja)
UY (1) UY27637A1 (ja)
WO (1) WO2003066599A1 (ja)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7804509A (nl) * 1978-04-26 1979-10-30 Acf Chemiefarma Nv Nieuwe 6,7-benzomorfanderivaten en zuuradditiezouten daarvan.
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
DE4122141C2 (de) * 1991-07-04 1999-05-27 Porsche Ag Abgasleitung einer Brennkraftmaschine
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19907874A1 (de) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma N-(5-Phenyl-tetrahydrofuranyl)methyl- und N-(6-Phenyl-tetrahydropyranyl)methyl substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6245777B1 (en) * 1999-02-23 2001-06-12 Boehringer Ingelheim Pharma Kg N-(5-phenyl-tetrahydrofuranyl)methyl- and N-(6-phenyl-tetrahydropyranyl)methyl-substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols
DE19957156A1 (de) * 1999-11-27 2001-05-31 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1474398A1 (de) 2004-11-10
WO2003066599A1 (de) 2003-08-14
CA2474687A1 (en) 2003-08-14
PE20030991A1 (es) 2004-01-27
TW200303203A (en) 2003-09-01
AR038381A1 (es) 2005-01-12
JP2005517013A (ja) 2005-06-09
AU2003215540A1 (en) 2003-09-02
UY27637A1 (es) 2003-08-29

Similar Documents

Publication Publication Date Title
EP0392059B1 (de) Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
DE69118889T2 (de) R(+)-terazosin
EP1622612B1 (de) Pharmazeutische formulierung des telmisartan natriumsalzes
DE69522511T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung von Xerostomie
EP1276476B1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
EP1442023B1 (de) Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist
EP1051170B1 (de) Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration
EP0607776A2 (de) Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
DD211783A5 (de) Verfahren zur herstellung von 2-/2'-hydroxy-3'-(1,1-dimethylpropylamino)-propoxy/-beta-phenylpropiophenon
EP1485057B9 (de) Derivate von aza-spiroverbindungen zur behandlung von schmerzen
EP0002672B1 (de) Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE9017900U1 (de) 3,4-Dihydro-1-benzyl-6,7-dimethoxy-α- [di-2-(2,3,4-trimethoxyphenyl)ethyl] aminocarbonyl-isochinolin
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
EP1157020B1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2749584A1 (de) Ueberbrueckte geminale diphenylpiperidine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP1471899B1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE10204276A1 (de) N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
DE1695785C3 (de) 2-Aminomethyl-beitzofurane, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Präparate
EP1100780B1 (de) 2,3,3a,4,9,9a-HEXAHYDRO-8-HYDROXY-1H-BENZ[F]INDOLE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
US6683089B2 (en) N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE19957156A1 (de) Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
EP0266563B1 (de) Verwendung von 1-Benzyl-amino-alkyl-pyrrolidinonen als Antidepressiva
DE2207460A1 (de) Neues lungentherapeutikum

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8139 Disposal/non-payment of the annual fee